Susan Thornton on Bridging the Knowledge Gap Between Researchers and Patients

A phase 2 trial found that some patients with classical Hodgkin lymphoma saw a nearly 74% probability of second remission due to retreatment with Keytruda.

Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”

The very first blog I ever wrote for CURE asked the question, “Why me?”

An expert from the Leukemia & Lymphoma Society breaks down the effectiveness of the COVID-19 vaccine in patients with blood cancers on this episode of the “Cancer Horizons” podcast.

I don’t know about you, but music moves me. Literally. It makes me move.

Survival outcomes and disparities for patients with blood cancers may depend on factors including insurance coverage, economic status and marital status.